These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8831378)

  • 1. Selective and nonselective dopamine receptor agonists: an innovative approach to cardiovascular disease treatment.
    Frishman WH; Hotchkiss H
    Am Heart J; 1996 Oct; 132(4):861-70. PubMed ID: 8831378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of dopamine receptors in the treatment of congestive heart failure.
    Goldberg LI
    J Cardiovasc Pharmacol; 1989; 14 Suppl 5():S19-27. PubMed ID: 2478806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular pharmacology of adrenergic and dopaminergic receptors: therapeutic significance in congestive heart failure.
    Lokhandwala MF; Hegde SS
    Am J Med; 1991 May; 90(5B):2S-9S. PubMed ID: 1675549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New dopamine agonists in cardiovascular therapy].
    Girbes AR; Van Veldhuisen DJ; Smit AJ
    Presse Med; 1992 Aug 29-Sep 5; 21(27):1287-91. PubMed ID: 1359528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic effects of selective dopamine receptor agonists in the rat and dog.
    Hieble JP; Owen DA; Harvey CA; Blumberg AL; Valocik RE; DeMarinis RM
    Clin Exp Hypertens A; 1987; 9(5-6):889-912. PubMed ID: 2887313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine: receptors and clinical applications.
    Goldberg LI
    Clin Physiol Biochem; 1985; 3(2-3):120-6. PubMed ID: 3159532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of DA1 receptors by dopamine or fenoldopam increases cyclic AMP levels in the renal artery but not in the superior cervical ganglion of the rat.
    Alkadhi KA; Sabouni MH; Ansari AF; Lokhandwala MF
    J Pharmacol Exp Ther; 1986 Aug; 238(2):547-53. PubMed ID: 2874213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor systems involved in norepinephrine release in heart failure: focus on dopaminergic systems.
    Francis GS
    Clin Cardiol; 1995 Mar; 18(3 Suppl I):I13-6. PubMed ID: 7743693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of dopaminergic and adrenergic receptors in the pathogenesis of arterial lesions induced by fenoldopam mesylate and dopamine in the rat.
    Kerns WD; Arena E; Morgan DG
    Am J Pathol; 1989 Aug; 135(2):339-49. PubMed ID: 2571297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenoldopam: a new dopamine agonist for the treatment of hypertensive urgencies and emergencies.
    Post JB; Frishman WH
    J Clin Pharmacol; 1998 Jan; 38(1):2-13. PubMed ID: 9597553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog.
    Nichols AJ; Smith JM; Shebuski RJ; Ruffolo RR
    J Pharmacol Exp Ther; 1987 Aug; 242(2):573-8. PubMed ID: 2886644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ibopamine--pharmacologic principles].
    Borchard U
    Z Kardiol; 1991; 80 Suppl 8():63-6. PubMed ID: 1686693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of ibopamine. A summary of experiments on anaesthesized dogs.
    Marchetti GV
    Cardiology; 1990; 77 Suppl 5():22-9. PubMed ID: 1980631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential use of DA1 and DA2 receptor agonists in the treatment of hypertension.
    Goldberg LI; Murphy MB
    Clin Exp Hypertens A; 1987; 9(5-6):1023-35. PubMed ID: 3304726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of l-stepholidine on the peripheral vascular dopamine DA1 and DA2 receptor subtypes].
    Zhang W; Zhi J; Guo W; Zhao R; Jin G
    Yao Xue Xue Bao; 1998 Oct; 33(10):721-6. PubMed ID: 12016922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurohormonal and hemodynamic effects of ibopamine.
    Pouleur H
    Clin Cardiol; 1995 Mar; 18(3 Suppl I):I17-21. PubMed ID: 7743694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine and dopamine receptor agonists in cardiovascular therapy.
    Murphy MB; Elliott WJ
    Crit Care Med; 1990 Jan; 18(1 Pt 2):S14-8. PubMed ID: 1967161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis of arterial lesions induced by dopaminergic compounds in the rat.
    Kerns WD; Arena E; Macia RA; Bugelski PJ; Matthews WD; Morgan DG
    Toxicol Pathol; 1989; 17(1 Pt 2):203-13. PubMed ID: 2568682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine: pharmacologic and therapeutic aspects.
    Velasco M; Luchsinger A
    Am J Ther; 1998 Jan; 5(1):37-43. PubMed ID: 10099036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of dopamine receptors and the utility of dopamine agonists in heart failure.
    Rajfer SI; Davis FR
    Circulation; 1990 Aug; 82(2 Suppl):I97-102. PubMed ID: 1973645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.